WO2006077101A3 - Ager-peptide und deren verwendung - Google Patents

Ager-peptide und deren verwendung Download PDF

Info

Publication number
WO2006077101A3
WO2006077101A3 PCT/EP2006/000420 EP2006000420W WO2006077101A3 WO 2006077101 A3 WO2006077101 A3 WO 2006077101A3 EP 2006000420 W EP2006000420 W EP 2006000420W WO 2006077101 A3 WO2006077101 A3 WO 2006077101A3
Authority
WO
WIPO (PCT)
Prior art keywords
ager
domains
protein
functionality
identification
Prior art date
Application number
PCT/EP2006/000420
Other languages
English (en)
French (fr)
Other versions
WO2006077101A2 (de
Inventor
Alfred Hahn
Ralph Loebbert
Nicole Teusch
Achim Moeller
Original Assignee
Abbott Gmbh & Co Kg
Alfred Hahn
Ralph Loebbert
Nicole Teusch
Achim Moeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510002353 external-priority patent/DE102005002353A1/de
Priority claimed from DE200510015832 external-priority patent/DE102005015832A1/de
Application filed by Abbott Gmbh & Co Kg, Alfred Hahn, Ralph Loebbert, Nicole Teusch, Achim Moeller filed Critical Abbott Gmbh & Co Kg
Priority to EP06706286A priority Critical patent/EP1838339A2/de
Priority to JP2007550773A priority patent/JP2008526243A/ja
Priority to US11/795,282 priority patent/US9291621B2/en
Publication of WO2006077101A2 publication Critical patent/WO2006077101A2/de
Publication of WO2006077101A3 publication Critical patent/WO2006077101A3/de
Priority to US14/993,308 priority patent/US20170008959A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Abstract

Die vorliegende Erfindung betrifft die Identifizierung, Funktionalität und Verwendung von Domänen aus dem N-Terminus des Rezeptors für Advanced Glycation End Products (AGER). Diese Domänen, mit der Bezeichnung Rezeptor Multimerisierungs Epitop (RME) sind hochkonserviert in sämtlichen AGER Proteinsequenzen. Sie stellen die Mediatoren für die AGER Selbstassoziation und Heteromerisierung mit anderen Proteinen dar. Ebenso betrifft die Erfindung die Identifizierung, Funktionalität und Verwendung von Peptiden, die von der C-Domäne von AGER abgeleitet sind (AGER-CDP). Die erfindungsgemäßen AGER-RMEs und AGER-CDPs eignen sich als Targets zur Identifizierung von AGER-Liganden, welche die natürliche Ligandenwechselwirkung modulieren; als Immunogen für die aktive oder passive Immunisierung von Individuen, als diagnostische Mittel zur Identifizierung immunogener Reaktionen sowie als Peptidliganden zur Modulation von Protein-Protein-Wechselwirkungen unter Beteiligung von AGER.
PCT/EP2006/000420 2005-01-18 2006-01-18 Ager-peptide und deren verwendung WO2006077101A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06706286A EP1838339A2 (de) 2005-01-18 2006-01-18 Ager-peptide und deren verwendung
JP2007550773A JP2008526243A (ja) 2005-01-18 2006-01-18 Ａｇｅｒペプチド及びその使用
US11/795,282 US9291621B2 (en) 2005-01-18 2006-01-18 AGER-peptides and use thereof
US14/993,308 US20170008959A1 (en) 2005-01-18 2016-01-12 Ager-peptides and use thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US64521105P 2005-01-18 2005-01-18
DE200510002353 DE102005002353A1 (de) 2005-01-18 2005-01-18 AGER-Rezeptor Multimerisierungs Epitope
US60/645,211 2005-01-18
DE102005002353.3 2005-01-18
US66870405P 2005-04-05 2005-04-05
US60/668,704 2005-04-05
DE102005015832.3 2005-04-06
DE200510015832 DE102005015832A1 (de) 2005-04-06 2005-04-06 AGER-Rezeptor Multimerisierungs Epitope
US68121105P 2005-05-13 2005-05-13
DE102005022285 2005-05-13
US60/681,211 2005-05-13
DE102005022285.4 2005-05-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/795,282 A-371-Of-International US9291621B2 (en) 2005-01-18 2006-01-18 AGER-peptides and use thereof
US14/993,308 Continuation US20170008959A1 (en) 2005-01-18 2016-01-12 Ager-peptides and use thereof

Publications (2)

Publication Number Publication Date
WO2006077101A2 WO2006077101A2 (de) 2006-07-27
WO2006077101A3 true WO2006077101A3 (de) 2006-09-28

Family

ID=36592929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/000420 WO2006077101A2 (de) 2005-01-18 2006-01-18 Ager-peptide und deren verwendung

Country Status (3)

Country Link
EP (1) EP1838339A2 (de)
JP (1) JP2008526243A (de)
WO (1) WO2006077101A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101463361B (zh) * 2009-01-14 2011-07-20 中国农业大学 双表达盒的表达载体及其制备方法与应用
CN101463362B (zh) * 2009-01-15 2011-07-20 中国农业大学 融合表达绿色荧光蛋白的表达载体及其构建方法与应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101649189B1 (ko) * 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039121A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
WO1997039125A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Antibodies against the advanced glycosylation end-product receptor and uses thereof
WO1999018987A1 (en) * 1997-10-09 1999-04-22 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO1999054485A1 (en) * 1998-04-17 1999-10-28 The Trustees Of Columbia University In The City Of New York A method for inhibiting tumor invasion or spreading in a subject
WO2001092892A2 (en) * 2000-05-30 2001-12-06 Transtech Pharma, Inc. Methods to identify compounds that modulate rage
US20030087302A1 (en) * 1998-10-05 2003-05-08 Ann Marie Schmidt Method for determing whether a compound is capable of inhibiting the interaction of a peptide with rage
JP2003230382A (ja) * 2002-02-08 2003-08-19 Univ Kanazawa Ａｇｅ−ｒａｇｅ拮抗剤
WO2004016229A2 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders
JP2004236791A (ja) * 2003-02-05 2004-08-26 Toray Ind Inc 糖尿病合併症因子吸着体

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039121A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
WO1997039125A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Antibodies against the advanced glycosylation end-product receptor and uses thereof
WO1999018987A1 (en) * 1997-10-09 1999-04-22 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO1999054485A1 (en) * 1998-04-17 1999-10-28 The Trustees Of Columbia University In The City Of New York A method for inhibiting tumor invasion or spreading in a subject
US20030087302A1 (en) * 1998-10-05 2003-05-08 Ann Marie Schmidt Method for determing whether a compound is capable of inhibiting the interaction of a peptide with rage
WO2001092892A2 (en) * 2000-05-30 2001-12-06 Transtech Pharma, Inc. Methods to identify compounds that modulate rage
JP2003230382A (ja) * 2002-02-08 2003-08-19 Univ Kanazawa Ａｇｅ−ｒａｇｅ拮抗剤
WO2004016229A2 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders
JP2004236791A (ja) * 2003-02-05 2004-08-26 Toray Ind Inc 糖尿病合併症因子吸着体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101463361B (zh) * 2009-01-14 2011-07-20 中国农业大学 双表达盒的表达载体及其制备方法与应用
CN101463362B (zh) * 2009-01-15 2011-07-20 中国农业大学 融合表达绿色荧光蛋白的表达载体及其构建方法与应用

Also Published As

Publication number Publication date
EP1838339A2 (de) 2007-10-03
JP2008526243A (ja) 2008-07-24
WO2006077101A2 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
WO2008119565A3 (en) Cross-species-specific binding domain
WO2010125036A3 (en) Plants having enhanced yield-related traits and a method for making the same
EP2573109A3 (de) Peptidvakzine mit der Seq Id 101, 80 or 100 für tumorassoziierte Antigene exprimierenden Krebs
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2008119567A8 (en) Cross-species-specific cd3-epsilon binding domain
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
PH12014501083A1 (en) Anticancer fusion protein
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
NZ591612A (en) Prevention, treatment and diagnosis of p.gingivalis infection with peptides
WO2007118660A3 (en) Her-2/neu multi-peptide vaccine
WO2006077101A3 (de) Ager-peptide und deren verwendung
WO2005123760A3 (en) Treating cancer
WO2005069187A3 (en) Methods and system for the identification and characterization of peptides and their functional relationships by use of measures of correlation
SG126893A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2010011994A3 (en) Polypeptides and uses thereof
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007550773

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006706286

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006706286

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11795282

Country of ref document: US